Skip to main content

Advertisement

SpringerLink
Log in

Need for improvements in reported cost effectiveness of adalimumab in rheumatoid arthritis

Notwendigkeit für Verbesserungen der berichteten Kosten-Nutzen-Bewertung von Adalimumab bei Rheumatoider Arthritis in Deutschland

  • Leserbrief
  • Published:
Zeitschrift für Rheumatologie Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Gülfe A, Wallman JK, Kristensen LE (2016) EuroQol-5 dimensions utility gain according to British and Swedish preference sets in rheumatoid arthritis treated with abatacept, rituximab, tocilizumab, or tumour necrosis factor inhibitors: a prospective cohort study from southern Sweden. Arthritis Res Ther 18:51

    Article  PubMed  PubMed Central  Google Scholar 

  2. Weinstein MC, O’Brien B, Hornberger J et al (2003) Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR task force on good research practices-modeling studies. Value Health 6:9–17

    Article  PubMed  Google Scholar 

  3. Philips Z, Ginnelly L, Sculpher M et al (2004) Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess 8:1–179

    Article  PubMed  Google Scholar 

  4. Statistisches Bundesamt (2016) Ergebnisse aus der laufenden Berechnung von Periodensterbetafeln für Deutschland und die Bundesländer. https://www.destatis.de/DE/Publikationen/Thematisch/Bevoelkerung/Bevoelkerungsbewegung/PeriodensterbetafelnBundeslaender512620414 7004.pdf?__blob=publicationFile. Accessed 24 June 2016

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Poliklinik für Rheumatologie, Hiller Research Unit for Rheumatology, Moorenstraße 5, 40225, Düsseldorf, Germany

    S. Weber, G. Pongratz, M. Schneider & R. Brinks

Authors
  1. S. Weber
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Pongratz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Schneider
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R. Brinks
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. Brinks.

Ethics declarations

Conflict of interest

S. Weber, G. Pongratz, M. Schneider, and R. Brinks declare that they have no competing interests.

Additional information

A reply to this comment can be found under doi:10.1007/s00393-016-0256-2

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Weber, S., Pongratz, G., Schneider, M. et al. Need for improvements in reported cost effectiveness of adalimumab in rheumatoid arthritis. Z Rheumatol 76, 183–184 (2017). https://doi.org/10.1007/s00393-016-0255-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00393-016-0255-3

Keywords

Search

Navigation